N/A N=451 Project Breast47: Effect of an Educational Intervention
Breast Neoplasm · Primary Prevention · Risk Factors
Primary: Behavioral BC Risk With an Educational Intervention for Prevention — 8.10; 8.15 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
N/A N=1,635 Breast Cancer Risk Reduction: A Patient Doctor Intervention
Breast Cancer
Primary: Knowledge of Breast Cancer Risk Factors — 48.9; 56.4 units on a scale
N/A N=1,001 Decision-aid on Breast Cancer Screening
Breast Cancer
Primary: Number of Participants With Adequate Knowledge — 236; 218 participants
Phase 2 N=48 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) — 6.6; 3.8 Months — p=0.12
N/A N=10 Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer
Breast Cancer
Primary: Residual Motion During Deep Inspiratory Breath-Hold (DIBH) — 0.27; 0.27 mm
N/A N=224 Breast Cancer: Feasibility of an Educational Intervention
Women's Health: Neoplasm of Breast
Primary: Feasibility of an Educational Intervention: Adherence to the Intervention — 99; 83 Participants
Phase 2 N=72 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67 — -1.2; -2.0 percentage of cells staining positive — p=0.71
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
N/A N=35 CairnSurgical Breast Cancer Locator (BCL) Post-Market Study
Breast Cancer
Primary: Positive Margin Rate — 2 Participants
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
N/A N=795 Association of Hepatitis C Virus With Breast Cancer
Breast Cancer · Hepatitis C
Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
N/A N=45 Individualizing Surveillance Mammography for Older Breast Cancer Survivors
Breast Cancer
Primary: Rate of Change in Intentions for Mammography in the Next Year — 39; 1 Participants
Phase 3 N=2,639 European Celecoxib Trial in Primary Breast Cancer
Breast Cancer
Primary: Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients. — 91; 90…
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
N/A N=59 The Breast Cancer Online Rehabilitation Program
Breast Cancer
Primary: Recruitment Rate — 35; 24 Participants
N/A N=220 AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival — 9.3 months
N/A N=284 Optimizing Functional Recovery of Breast Cancer Survivors
Breast Cancer Female
Primary: Participation Satisfaction in Social Roles and Activities: PROMIS — 45.75; 46; 48.09; 47.61 T-score — p=.54
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
N/A N=206 Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
Breast Cancer
Primary: Local Inbreast Breast Tumor Recurrence (IBTR) Rate — 4.3 Percentage of participants with IBTR
N/A N=1,832 Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
Breast Cancer
Primary: Overall Survival — 82; 83 percentage of alive at 10 years — p=0.38
N/A N=89 Clinical Utility of a Low-Cost Hand-Held Breast Scanner
Symptomatic Breast Lump
Primary: Number of Quadrants With Detected Breast Lesions — 77; 265 quadrants
N/A N=132 Breast Cancer Genome Guided Therapy Study (BEAUTY)
Invasive Breast Cancer
Primary: DNA From the Germline and Breast Tumor for the Identification of Novel Somatic Changes Within Gene and Gene Pathways. — 3 mutations
Phase 2 N=17 Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 2 participants
Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
N/A N=1,007 Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
Breast Cancer · Contralateral Breast Cancer
Primary: MRI Diagnostic Yield of Cancers in the Contralateral Breast — 30; 114; 3; 822 Participants
N/A N=670 Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
Breast Cancer Related Lymphedema · Covid19
Primary: COVID-19 Vaccination on Contralateral vs Ipsilateral Arm — 432; 435; 331; 122 Participants